Issue 23

Are Activist Investors Good News for CDMOs?

Why not sign up for our future email newsletters? Sign up here.

In this issue:

LEAD STORY

Activist Investors Eyeing Big Pharma: What It Means for the Industry

Last month, hedge fund Starboard Value acquired a $1 bn stake in Pfizer, at the same time, sharply criticizing the company's management for recent underperformance and strategic missteps. According to Starboard, Pfizer has seen at least $20 bn in value evaporate since 2019. 

Read more here.

FEATURED STORIES

Jim Petrilla Joins Vernal Biosciences as CEO

Read more here.

Bora Pharmaceuticals Expands Rare Disease Reach with Pyros Pharmaceuticals Acquisition

Read more here.

Laurus Labs Expands Product Portfolio & Boosts CDMO Capabilities

Read more here.

CDMO Samsung Biologics Bags $1.2B Contract, Boosting 2024 Value to Over $3.3B

Read more here.

UK's Labour Party Unveils £520 Million Innovative Manufacturing Fund in Life Science-Heavy Budget

Read more here.

Rentschler Biopharma to Build State-of-the-Art Buffer Media Station in Laupheim

Read more here.

MilliporeSigma Invests $76 mn to Triple ADC Production Capacity

Read more here.

NorthStar Medical Radioisotopes Opens New Radiopharmaceutical CDMO Facility 

Read more here.

Piramal Pharma Commits $85 Million for Capacity Expansion and Growth

Read more here.

ROVI Retains CDMO Business – Rejecting 5 Offers for Sale

Read more here.

Celltrion Secures $73 Million CDMO Deal

Read more here.

FDA Removes Wegovy from Shortage List as Novo Nordisk Resolves Supply Issues

Read more here.

Matica Bio and KaliVir Partner to Advance Oncolytic Virus Manufacturing for Cancer Therapies

Read more here.